Mizuho Securities Raises Price Target on Sucampo Pharma (SCMP) Following 3Q Beat and Raise
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Jabil falls after placing CEO on paid leave amid internal investigation
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- NVIDIA (NVDA) Shares Extend Drop To 10%, Erasing $212 Billion In Value - Bloomberg
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Sucampo Pharmaceuticals (SCMP) PT Raised to $19 at Maxim Group
November 15, 2016 7:33 AM ESTMaxim Group analyst Jason Kolbert reiterated a Buy rating and raised his price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) to $19.00 (from $17.00).
Kolbert highlighted:
Sucampo reported 3Q16 results with total revenues of $57.9M, up 11% sequentially, which we consider to be good sequential growth. Total revenues included product sales of $31.6M ($29.1M from AMITIZA) and royalty revenue of $20.8M from Takeda. The quarterly revenues include an additional $13.3M from the R-Tech Ueno acquisition. While AMITIZA total... MoreJefferies Raises Price Target on Sucampo Pharma (SCMP) Following 3Q Report
November 10, 2016 10:10 AM ESTJefferies reiterated a Hold rating on Sucampo Pharmaceuticals (NASDAQ: SCMP), and raised the price target to $16.00 (from $14.00), following the company's 3Q earnings report. SCMP reported 3Q EPS of $0.28, compared to Jefferies' $0.25 estimate. Revenues of $58M, +$7M ahead of estimates. Based on the Q3... More